首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Additive Effect of Qidan Dihuang Grain a Traditional Chinese Medicine and Angiotensin Receptor Blockers on Albuminuria Levels in Patients with Diabetic Nephropathy: A Randomized Parallel-Controlled Trial
【2h】

Additive Effect of Qidan Dihuang Grain a Traditional Chinese Medicine and Angiotensin Receptor Blockers on Albuminuria Levels in Patients with Diabetic Nephropathy: A Randomized Parallel-Controlled Trial

机译:中药契丹地黄颗粒与血管紧张素受体阻滞剂对糖尿病肾病患者蛋白尿水平的加和作用:一项随机对照试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Albuminuria is characteristic of early-stage diabetic nephropathy (DN). The conventional treatments with angiotensin receptor blockers (ARB) are unable to prevent the development of albuminuria in normotensive individuals with type 2 diabetes mellitus (T2DM). Purpose. The present study aimed to evaluate the effect of ARB combined with a Chinese formula Qidan Dihuang grain (QDDHG) in improving albuminuria and Traditional Chinese Medicine Symptom (TCMS) scores in normotensive individuals with T2DM. Methods. Eligible patients were randomized to the treatment group and the control group. Results. Compared with baseline (week 0), both treatment and control groups markedly improved the 24-hour albuminuria, total proteinuria (TPU), and urinary albumin to creatinine ratio (A/C) at 4, 8, and 12 weeks. Between treatment and the control group, the levels of albuminuria in the treatment group were significantly lower than in the control group at 8 and 12 weeks (p < 0.05). In addition, treatment group markedly decreased the scores of TCMS after treatment. Conclusion. This trial suggests that QDDHG combined with ARB administration decreases the levels of albuminuria and the scores for TCMS in normotensive individuals with T2DM.
机译:蛋白尿是早期糖尿病肾病(DN)的特征。使用血管紧张素受体阻滞剂(ARB)的常规治疗无法预防2型糖尿病(T2DM)血压正常个体中蛋白尿的发展。目的。本研究旨在评估ARB联合中药芪丹地黄颗粒(QDDHG)对改善血压正常的T2DM患者的蛋白尿和中医症状(TCMS)评分的作用。方法。符合条件的患者被随机分为治疗组和对照组。结果。与基线(第0周)相比,治疗组和对照组在第4、8和12周时均显着改善了24小时蛋白尿,总蛋白尿(TPU)和尿白蛋白与肌酐的比率(A / C)。在治疗和对照组之间,在第8周和第12周,治疗组的蛋白尿水平显着低于对照组(p <0.05)。另外,治疗组治疗后TCMS评分明显降低。结论。该试验表明,QDDHG与ARB联合使用可降低血压正常的T2DM患者的蛋白尿水平和TCMS评分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号